New drug aims to tame rare inflammatory disease EGPA
NCT ID NCT05979051
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, SHR-1703, for people with eosinophilic granulomatosis with polyangiitis (EGPA), a rare disease that causes inflammation in blood vessels. The trial will include 166 adults who have not responded well to standard treatments. The goal is to see if SHR-1703 can help reduce the need for steroids and bring the disease under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-1703 (a drug given by injection under the skin)
- What this could lead to
- If successful, this could offer a new treatment option for EGPA, potentially reducing the need for high-dose steroids and helping more patients achieve remission.
- What could go wrong
- This is an early-to-mid-stage trial with only 166 participants, so results may not apply to everyone. The drug's safety and effectiveness are not yet proven, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for rare disease: can NS-229 help patients reduce steroids?
- New study tracks Nucala's Long-Term impact on rare inflammatory disease
- Scientists build tissue bank to unlock vasculitis mysteries
- Scientists hunt for clues to rare immune disease
- New drug MT-2990 tested in rare blood vessel disease
- Statin trial targets hidden heart risk in vasculitis patients